Incyte Corp
INCY: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$12.00 | Bwpmxl | Kffczvyv |
Incyte's Jakafi and Growing Oncology and Dermatology Portfolio Support a Narrow Moat
Business Strategy and Outlook
Incyte's lead drug, Jakafi, initially gained traction in 2011 as the only drug approved for severe myelofibrosis, a rare blood disorder. Jakafi's stronghold of the MF market is likely to continue, although new drugs are entering the market for subsets of the population. Incyte expanded Jakafi’s label to polycythemia vera (2014), steroid refractory acute graft versus host disease (2019), and chronic GvHD (2021) should together push peak U.S. sales to nearly $3.5 billion.